I. Durand-zaleski

发表

Technology assessment in health care--decision makers and health care providers: what they need to know.

I. Durand-zaleski, D. Jolly, 1990, Health policy.

Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues.

I. Durand-zaleski, D. Jolly, C. Chaix-couturier, 2000, International journal for quality in health care : journal of the International Society for Quality in Health Care.

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

John V. White, H. Sillesen, I. Durand-zaleski, 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Evaluating Structured Care for Diabetes: Can Calibration on Margins Help to Avoid Overestimation of the Benefits? An Illustration From French Diabetes Provider Networks Using Data From the ENTRED Survey

I. Durand-zaleski, E. Nolte, K. Chevreul, 2014, Diabetes Care.

I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.

I. Durand-zaleski, P. Baas, S. Ekman, 2019, Future oncology.

Cost of stroke in France

M. Hommel, I. Durand-zaleski, F. Woimant, 2013, European journal of neurology.

Management of end-stage heart failure patients with or without ventricular assist device: an observational comparison of clinical and economic outcomes†

Isabelle Durand-Zaleski, Uwe Schulz, Pascal Leprince, 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Comparison of two data collection processes in clinical studies: electronic and paper case report forms

Corinne Alberti, Isabelle Durand-Zaleski, I. Durand-zaleski, 2014, BMC Medical Research Methodology.

Cost-effectiveness of point-of-care viscoelastic haemostatic assays in the management of bleeding during cardiac surgery: protocol for a prospective multicentre pragmatic study with stepped-wedge cluster randomised controlled design and 1-year follow-up (the IMOTEC study)

I. Durand-zaleski, B. Rozec, K. Lakhal, 2019, BMJ Open.

Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations.

I. Durand-zaleski, I. Vedel, O. Montagne, 1999, Clinical therapeutics.

Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis.

I. Durand-zaleski, X. Bertagna, P. Legmann, 2005, European journal of endocrinology.

Managing toxic thyroid adenoma: a cost-effectiveness analysis.

I. Durand-zaleski, J. Stahl, G. Vidal-Trécan, 2002, European journal of endocrinology.

Comparative efficacy studies with irbesartan for the treatment of hypertension

I. Durand-zaleski, O. Pirk, C. Hacker, 2009 .

Ethanol versus radiofrequency ablation for the treatment of small hepatocellular carcinoma in patients with cirrhosis: a retrospective study of efficacy and cost.

I. Durand-zaleski, O. Seror, J. Trinchet, 2006, Gastroenterologie clinique et biologique.

Tele-expertise for diagnosis of skin lesions is cost-effective in a prison setting: A retrospective cohort study of 450 patients

I. Durand-zaleski, K. Zarca, N. Charrier, 2018, PloS one.

Implantable cardioverter-defibrillators in France: practices and regional variability.

A. Lazarus, I. Durand-zaleski, M. Chauvin, 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study

I. Durand-zaleski, M. Bertrand, 2012, PharmacoEconomics.

Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments.

I. Durand-zaleski, P. Marino, L. Perrier, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Costs of Nosocomial Infections in the ICU and Impact of Programs to Reduce Risks and Costs

C. Brun-Buisson, I. Durand-zaleski, C. Chaix, 2002 .

Organisation and delivery of imaging services: the contributions of ethics and political economy.

I. Durand-zaleski, 2009, Radiation protection dosimetry.

Evaluating chronic disease management in real-world settings in six European countries: Lessons from the collaborative DISMEVAL project

C. Knai, I. Durand-zaleski, J. Adams, 2014 .

An economic evaluation of tranexamic acid to prevent postpartum haemorrhage in women with vaginal delivery: the randomised controlled TRAAP trial

I. Durand-zaleski, L. Sentilhes, C. Deneux-Tharaux, 2020, BJOG : an international journal of obstetrics and gynaecology.

Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial.

A. Íñiguez, I. Durand-zaleski, M. Morice, 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies.

L. Abenhaim, D. Lamping, J. Cooke, 1999, International angiology : a journal of the International Union of Angiology.

Efficacy and cost effectiveness of telemedicine for improving access to care in the Paris region: study protocols for eight trials

I. Durand-zaleski, K. Zarca, N. Charrier, 2015, BMC Health Services Research.

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

I. Durand-zaleski, F. Cotté, A. Gaudin, 2014, Journal of medical economics.

Cost‐effectiveness of five prenatal screening strategies for trisomies and other unbalanced chromosomal abnormalities: model‐based analysis

Y. Ville, I. Durand-zaleski, C. Elie, 2019, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

Statistical analysis plan for the EuroHYP-1 trial: European multicentre, randomised, phase III clinical trial of the therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke

M. Macleod, S. Schwab, I. Durand-zaleski, 2017, Trials.

Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial.

S. Cook, I. Durand-zaleski, P. Sinnaeve, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention

I. Durand-zaleski, E. Teiger, S. Marque, 2016, Open Heart.

Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.

E. Vicaut, I. Durand-zaleski, G. Lemesle, 2021, JAMA.

Peer Review of Grant Applications: Criteria Used and Qualitative Study of Reviewer Practices

F. Tubach, I. Durand-zaleski, C. Alberti, 2012, PloS one.

Mental health disorders research in Europe, 2001–2018

G. Lewison, I. Durand-zaleski, R. Sullivan, 2020, Evidence-Based Mental Health.

Public and nonprofit funding for research on mental disorders in France, the United Kingdom, and the United States.

Carrie M. Farmer, D. Kupfer, M. Leboyer, 2012, The Journal of clinical psychiatry.

Hospital bad debt in France: who does not pay?

F. Lemaire, I. Durand-zaleski, 1993, Health policy.

HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies

S. Palmer, L. Garrison, I. Durand-zaleski, 2020, The European Journal of Health Economics.

The Economic Impact and Health-Related Quality of Life of Spinal Muscular Atrophy. An Analysis across Europe

I. Durand-zaleski, E. Tizzano, S. Litzkendorf, 2020, International journal of environmental research and public health.

Hereditary angioedema: Clinical presentation and socioeconomic cost of 200 French patients.

E. Vicaut, I. Durand-zaleski, F. Lapostolle, 2019, The journal of allergy and clinical immunology. In practice.

Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster‐Randomized Controlled Trial

E. Vicaut, I. Durand-zaleski, B. Floccard, 2018, Annals of emergency medicine.

Randomized clinical trial of ultrasonic scissors versus conventional haemostasis to compare complications and economics after total thyroidectomy (FOThyr)

C. Volteau, F. Pattou, I. Durand-zaleski, 2017, BJS open.

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France

I. Durand-zaleski, E. Thervet, F. Maunoury, 2018, PloS one.

Transcultural mediation programme in a paediatric hospital in France: qualitative and quantitative study of participants’ experience and impact on hospital costs

I. Durand-zaleski, M. Moro, P. de Lonlay, 2019, BMJ Open.

Is Europe Putting Theory Into Practice

Andreas Sönnichsen, Ellen Nolte, Isabelle Durand-Zaleski, 2013 .

Prevention of Early Ventilator-Associated Pneumonia after Cardiac Arrest.

B. Giraudeau, I. Durand-zaleski, C. Guitton, 2019, The New England journal of medicine.

DEALE-ing and Discounting

I. Durand-zaleski, S. Zaleski, 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV‐Infected Patients in the VIRADAPT Study

J. Schapiro, I. Durand-zaleski, P. Clevenbergh, 2000, Journal of acquired immune deficiency syndromes.

A tale of two countries: costs and financial incentives for provisional stenting during percutaneous coronary intervention in France and the United States

M. Kern, I. Durand-zaleski, J. Dubois-Randé, 2002, The European Journal of Health Economics.

Impact of Point‐of‐care Testing on Length of Stay of Patients in the Emergency Department: A Cluster‐randomized Controlled Study

I. Durand-zaleski, A. Lafourcade, B. Riou, 2020, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

SOR Project: the French context

I. Durand-zaleski, T. Philip, 2001, British Journal of Cancer.

Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases

I. Durand-zaleski, K. Chevreul, Benjamin Cadier, 2016, PloS one.

[Neonatal screening of severe combined immunodeficiencies].

I. Durand-zaleski, N. Mahlaoui, A. Fischer, 2015, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

Inborn Errors of Amino Acid Metabolism: The Best Strategy for Their Diagnosis

I. Durand-zaleski, P. Kamoun, J. Saudubray, 1992, International Journal of Technology Assessment in Health Care.

Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. Does low risk mean high cost?

S G Pauker, M H Eckman, S. Pauker, 1990, JAMA.

Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial.

C. Marquette, J. Vergnon, L. Thiberville, 2016, Journal of the American Medical Association (JAMA).

Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population.

Y. Ville, S. Chevret, H. Cuckle, 2006, American journal of obstetrics and gynecology.

Misconstructions in health economics applied to the evaluation of prenatal screening

I. Durand-zaleski, 2006, Expert review of pharmacoeconomics & outcomes research.

Economic Assessment of Magnetic Resonance Imaging for Inpatients: Is It Still Too Early?

I. Durand-zaleski, D. Reizine, J. Merland, 1993, International Journal of Technology Assessment in Health Care.

Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia

I. Durand-zaleski, H. Esperou, C. Cordonnier, 2005, Bone Marrow Transplantation.

[Ultrasound screening for birth defects: A medico-economic review].

F. Dhombres, I. Durand-zaleski, C. Ferrier, 2017, Gynecologie, obstetrique, fertilite & senologie.

Induction of labour with a viable infant: a randomised clinical trial comparing intravaginal misoprostol and intravaginal dinoprostone

Y. Ville, S. Chevret, C. Chastang, 2001, BJOG : an international journal of obstetrics and gynaecology.

Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

A. Luciani, V. Vilgrain, I. Durand-zaleski, 2022, Cancers.

Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints.

S. Pauker, I. Durand-zaleski, J. Tsevat, 1989, American journal of public health.

Ambulatory transradial percutaneous coronary intervention: A safe, effective, and cost‐saving strategy

P. Lesault, I. Durand-zaleski, A. Duval, 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Cost-effectiveness of New Surgical Treatments for Hemorrhoidal Disease: A Multicentre Randomized Controlled Trial Comparing Transanal Doppler-guided Hemorrhoidal Artery Ligation With Mucopexy and Circular Stapled Hemorrhoidopexy

I. Durand-zaleski, L. Siproudhis, J. Hardouin, 2016, Annals of surgery.

High technology in health care.

I. Durand-zaleski, D. Jolly, 1990, Quality assurance in health care : the official journal of the International Society for Quality Assurance in Health Care.

International Study of Health Care Organization and Financing for end-stage renal disease in France

I. Durand-zaleski, C. Combe, P. Lang, 2007, International Journal of Health Care Finance and Economics.

Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial

A. Cremer, P. Gosse, G. Chatellier, 2017, Journal of the American Heart Association.

Paresis acquired in the intensive care unit: a prospective multicenter study.

Isabelle Durand-Zaleski, Charles Cerf, Jean-Pascal Lefaucheur, 2002, JAMA.

Effectiveness and efficiency of tele-expertise for improving access to retinopathy screening among 351 neonates in a secondary care center: An observational, controlled before-after study

I. Durand-zaleski, P. Jarreau, G. Caputo, 2018, PloS one.

The Economic Impact and Health-Related Quality of Life of Spinal Muscular Atrophy. An Analysis across Europe

I. Durand-zaleski, E. Tizzano, S. Litzkendorf, 2020, International journal of environmental research and public health.

Why cost-of-illness studies are important and inform policy

I. Durand-zaleski, 2008, Vascular medicine.

Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study

I. Durand-zaleski, P. Cottu, M. Gutiérrez, 2013, BMC Health Services Research.

Effectiveness and cost-effectiveness of telephone consultations for fever or gastroenteritis using a formalised procedure in general practice: study protocol of a cluster randomised controlled trial

E. Vicaut, I. Durand-zaleski, F. Lapostolle, 2016, Trials.

Cost and Effectiveness of Intrapartum Group B Streptococcus Polymerase Chain Reaction Screening for Term Deliveries

I. Durand-zaleski, L. Gutmann, K. Guyot, 2012, Obstetrics and gynecology.

Left Ventricular Rapid Pacing Via the Valve Delivery Guidewire in Transcatheter Aortic Valve Implantation

I. Durand-zaleski, E. Belle, G. Souteyrand, 2019 .

Factors predictive of macrosomia in pregnancies with a positive oral glucose challenge test: importance of fasting plasma glucose.

I. Durand-zaleski, L. Mandelbrot, H. Legardeur, 2014, Diabetes & metabolism.

The Burden of Spinal Muscular Atrophy on Informal Caregivers

I. Durand-zaleski, E. Tizzano, S. Litzkendorf, 2020, International journal of environmental research and public health.

Infection Risk and Cost-Effectiveness of Commercial Bags or Glass Bottles for Total Parenteral Nutrition

C. Brun-Buisson, I. Durand-zaleski, O. Langeron, 1997, Infection Control & Hospital Epidemiology.

Prevalence of rare mitochondrial DNA mutations in mitochondrial disorders

Marni J. Falk, A. Rötig, I. Durand-zaleski, 2013, Journal of Medical Genetics.

Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome

F. Bolgert, I. Durand-zaleski, H. Esperou, 2000, Intensive Care Medicine.

[Economic burden of COPD: the SCOPE study].

I. Durand-zaleski, B. Housset, P. Godard, 2005, Revue des maladies respiratoires.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program

P. Casán, J. Bourbeau, I. Durand-zaleski, 2019, International journal of chronic obstructive pulmonary disease.

Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial.

C. Marquette, J. Vergnon, L. Thiberville, 2016, JAMA.

Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)

A. Cuvelier, N. Roche, C. Marquette, 2018, Respiratory Research.

[Cost-effectiveness of lung volume reduction coil treatment in emphysema. STIC REVOLENS].

C. Marquette, J. Vergnon, L. Thiberville, 2012, Revue des maladies respiratoires.

Association between mental disorders and COVID-19 outcomes among inpatients in France: A retrospective nationwide population-based study

M. Leboyer, C. Laidi, O. Godin, 2022, Journal of Psychiatric Research.

Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial.

G. Chatellier, I. Durand-zaleski, G. Montalescot, 2019, American heart journal.

Cost-utility analysis of a Home-based disease management intervention for patients with severe COPD in the COMET study.

J. Bourbeau, I. Durand-zaleski, S. Roze, 2018, Ethics and Economics.

Evaluation Units in French Hospitals: Experiences and Limitations

I. Durand-zaleski, P. Durieux, 1999 .

Economic evaluation of fractional flow reserve-guided versus angiography-guided multivessel revascularisation in ST-segment elevation myocardial infarction patients in the FLOWER-MI randomised trial.

G. Chatellier, I. Durand-zaleski, G. Montalescot, 2022, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

A Multicenter Randomized Trial Assessing the Efficacy of Helium/Oxygen in Severe Exacerbations of Chronic Obstructive Pulmonary Disease

J. Chiche, L. Brochard, C. Brun-Buisson, 2017, American journal of respiratory and critical care medicine.

Point-of-Care Intrapartum Group B Streptococcus Molecular Screening: Effectiveness and Costs.

I. Durand-zaleski, A. Le Monnier, E. Azria, 2019, Obstetrics and gynecology.

ofAntibiotic Prophylaxis forDentalProcedures inPatients withArtificial Joints

I. Durand-zaleski, 1989 .

Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis.

S. Pauker, A. Levey, D. Snydman, 1991, Transplantation.

The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation

I. Durand-zaleski, C. Pouteil‐Noble, A. Richter, 2005, The European Journal of Health Economics.

Costs and benefits of On-Demand HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men Analysis of the ANRS IPERGAY study with a one-year follow-up.

C. Tremblay, I. Durand-zaleski, B. Spire, 2018, AIDS.

Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.

N. Girard, I. Durand-zaleski, J. Penrod, 2022, Lung cancer.

Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction.

G. Chatellier, I. Durand-zaleski, G. Lemesle, 2021, The New England journal of medicine.

Direct Treatment Costs for Patients with Lung Cancer from First Recurrence to Death in France

I. Durand-zaleski, J. Trédaniel, P. Piedbois, 2012, PharmacoEconomics.

P.Rozenberg1,9, L.Malagrida1, H.Cuckle2, I.Durand-Zaleski3, I.Nisand1, F.Audibert4, C.Benattar4, S.Tribalat5, M.Cartron5, P.Lemarié6, J.Stoessel6, P.Capolagui6, J.Jansé-Marec7, D.Barbier7, C.Allouch8, M.Perdu1, A.Roberto1, Z.Lahna1, Y.Giudicelli1 and Y.Ville1

Y. Ville, H. Cuckle, I. Durand-zaleski, 2002 .

The management of chronic venous disorders of the leg: An evidence-based report of an international Task Force

L. Abenhaim, D. Lamping, J. Cooke, 1999 .

Cost-effectiveness of strategies to control the spread of carbapenemase-producing Enterobacterales in hospitals: a modelling study

I. Durand-zaleski, S. Kernéis, J. Lucet, 2022, Antimicrobial Resistance & Infection Control.

Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on French real field data.

A. Fischer, I. Durand-zaleski, N. Mahlaoui, 2015, The Journal of allergy and clinical immunology.

A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia.

I. Durand-zaleski, L. Norgren, G. Fowkes, 2003, International angiology : a journal of the International Union of Angiology.

A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis).

I. Durand-zaleski, G. Fowkes, J. Dormandy, 2000, International angiology : a journal of the International Union of Angiology.

Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid:

I. Durand-zaleski, R. Moreau, D. Valla, 2006, Liver international : official journal of the International Association for the Study of the Liver.

HIV-1 drug resistance genotyping. A review of clinical and economic issues.

I. Durand-zaleski, C. Chaix-couturier, K. Phillips, 2000, PharmacoEconomics.

Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Immune Thrombocytopenia Working Group.

I. Durand-zaleski, C. Kaplan, S. Uzan, 1996, American journal of perinatology.

PREDICTING THE COSTS OF ALLOGENEIC SIBLING STEM-CELL TRANSPLANTATION: RESULTS FROM A PROSPECTIVE, MULTICENTER, FRENCH STUDY

S. Chevret, F. Roudot-thoraval, I. Durand-zaleski, 2004, Transplantation.

Reply to: «Screening for Hepatocellular carcinoma: A drug safety issue».

I. Durand-zaleski, P. Nahon, O. Seror, 2017 .

Impact of sodium 18F-fluoride PET/CT, 18F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study

O. Cussenot, I. Durand-zaleski, F. Lecouvet, 2018, World Journal of Urology.

How to collect non-medical data in a pediatric trial: diaries or interviews

I. Durand-zaleski, N. Tubiana-Rufi, C. Alberti, 2020, Trials.

Estimating indirect costs in a pediatric trial: patient diaries and interview data collection

I. Durand-zaleski, N. Tubiana-Rufi, S. Guilmin-Crépon, 2019 .

Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles

M. Loriot, I. Durand-zaleski, N. Pallet, 2020, Pharmacogenetics and genomics.

Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis

G. Chatellier, M. Loriot, I. Durand-zaleski, 2019, Molecular Diagnosis & Therapy.

Lack of multiplicative transitivity in person trade-off responses.

I. Durand-zaleski, E. Nord, J. Lanöe, 2004, Health economics.

Cost and outcomes of the ultrasound screening program for birth defects over time: a population-based study in France

F. Dhombres, I. Durand-zaleski, C. Ferrier, 2020, BMJ Open.

Lung CAncer SCreening in French women using low-dose CT and Artificial intelligence for DEtection: the CASCADE study protocol

M. Revel, I. Durand-zaleski, G. Chassagnon, 2022, BMJ Open.

France: Health system review.

I. Durand-zaleski, K. Chevreul, P. Mladovsky, 2010, Health systems in transition.

Thirty day Outcomes and Costs of Fenestrated and Branched Stent Grafts versus Open Repair for Complex Aortic Aneurysms

I. Durand-zaleski, J. Becquemin, C. Quélen, 2015 .

Evaluation of the T-cell receptor excision circle assay performances for severe combined immunodeficiency neonatal screening on Guthrie cards in a French single centre study.

A. Fischer, I. Durand-zaleski, N. Mahlaoui, 2014, Clinical immunology.

Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.

A. Rahmouni, I. Durand-zaleski, N. Vasile, 1995, Nephron.

Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group.

I. Durand-zaleski, C. Kaplan, G. Tchernia, 1997, Blood.

A novel personalized approach to cardiovascular prevention: The VIVOPTIM programme.

I. Durand-zaleski, J. Blacher, A. Dibié, 2020, Archives of cardiovascular diseases.

Cost effectiveness of full coverage of the medical management of smoking cessation in France

I. Durand-zaleski, K. Chevreul, Benjamin Cadier, 2012, Tobacco Control.

Nonprocurement of transplantable organs in a tertiary care hospital: a focus on sociological causes.

I. Durand-zaleski, P. Lang, F. Bonnet, 1996, Transplantation.

Srce i krvni Sudovi

F. Eberli, I. Durand-zaleski, A. Colombo, 2013 .

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

Noor A. Jatoi, D. Šuput, M. Dimopoulos, 2020, Thrombosis and Haemostasis.

Cost-effectiveness analysis of hip fracture prevention with vitamin D supplementation: a Markov micro-simulation model applied to the French population over 65 years old without previous hip fracture

C. Benhamou, I. Durand-zaleski, C. Roux, 2014, Osteoporosis International.

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience

G. Chatellier, P. Laurent-Puig, I. Durand-zaleski, 2013, PloS one.

Evaluating chronic disease management: Recommendations for funders and users

C. Knai, I. Durand-zaleski, J. Adams, 2012 .

Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial

C. Brun-Buisson, I. Durand-zaleski, J. Pottecher, 2017, Intensive Care Medicine.

Prevalence and Risk Factors for Carriage of Methicillin-Resistant Staphylococcus aureus at Admission to the Intensive Care Unit

S. Chevret, C. Chastang, I. Durand-zaleski, 2016 .

Does intraoperative neuromonitoring of recurrent nerves have an impact on the postoperative palsy rate? Results of a prospective multicenter study

C. Volteau, F. Pattou, I. Durand-zaleski, 2018, Surgery.

Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.

I. Durand-zaleski, E. Nicod, P. Kanavos, 2017, Value in Health.

I. Durand-zaleski, K. Chevreul, Ane Auraaen, 2014, International journal of environmental research and public health.

Fixed price contracts: the case of pediatric acute lymphoblastic leukemia.

I. Durand-zaleski, 1992, Health policy.

viscoelastic haemostatic assays in the management of bleeding during cardiac surgery: protocol for a prospective multicentre pragmatic study with stepped-

I. Durand-zaleski, B. Rozec, K. Lakhal, 2019 .

Cost-Effectiveness of Mass Screening for Colorectal Cancer: Choice of Fecal Occult Blood Test and Screening Strategy

I. Sobhani, I. Durand-zaleski, I. Ghout, 2011, Diseases of the colon and rectum.

Termination of pregnancy following prenatal diagnosis in France: how severe are the foetal anomalies?

I. Durand-zaleski, L. Mandelbrot, M. Dommergues, 2010, Prenatal diagnosis.

EuroHYP-1: European Multicenter, Randomized, Phase III Clinical Trial of Therapeutic Hypothermia plus Best Medical Treatment vs. Best Medical Treatment Alone for Acute Ischemic Stroke

D. Krieger, M. Macleod, S. Schwab, 2014, International journal of stroke : official journal of the International Stroke Society.

Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit.

C. Brun-Buisson, I. Durand-zaleski, C. Alberti, 1999, JAMA.

How Should we Use Multicolumn Spinal Cord Stimulation to Optimize Back Pain Spatial Neural Targeting? A Prospective, Multicenter, Randomized, Double‐Blind, Controlled Trial (ESTIMET Study)

E. Cuny, P. Mertens, F. Caire, 2020, Neuromodulation : journal of the International Neuromodulation Society.

Hereditary angioedema, emergency management of attacks by a call center.

E. Vicaut, I. Durand-zaleski, B. Floccard, 2019, European journal of internal medicine.

Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial

E. Vicaut, I. Durand-zaleski, B. Floccard, 2016, Trials.

Cost evaluation of the medical management of neurofibromatosis 1: a prospective study on 201 patients

I. Durand-zaleski, J. Zeller, J. Revuz, 2000, The British journal of dermatology.

Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study.

J. Schapiro, I. Durand-zaleski, P. Clevenbergh, 2000 .

[Unilateral inguinal hernia in infants: costs, risks and benefits of herniography? Methodology].

I. Durand-zaleski, O. Lucidarme, J. Montagne, 1995, Journal de radiologie.

Impact of the switch from four to three intradermal rabies post-exposure prophylaxis sessions in patients bitten by dogs: A cost-consequence analysis from the patients' perspective

I. Durand-zaleski, K. Zarca, Malen Chan, 2022, One health.

Reported barriers to evaluation in chronic care: experiences in six European countries.

C. Knai, I. Durand-zaleski, A. Sarría-Santamera, 2013, Health policy.

Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study.

J. Le Heuzey, I. Durand-zaleski, J. Dallongeville, 2010, Archives of cardiovascular diseases.

Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France.

I. Durand-zaleski, F. Cotté, A. Gaudin, 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Costs and Benefits of Measures to Prevent Needlestick Injuries in a University Hospital

F. Roudot-thoraval, I. Durand-zaleski, O. Montagne, 1999, Infection Control & Hospital Epidemiology.

Markov Models for Health Economic Evaluations: The R Package heemod

Isabelle Durand-Zaleski, Antoine Filipovi'c-Pierucci, Kevin Zarca, 2017, 1702.03252.

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)

I. Durand-zaleski, P. Chauvin, P. Souquet, 2017, PloS one.

Correction: Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Patricia Marino, Rajae Touzani, Lionel Perrier, 2018, European Journal of Human Genetics.

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Dede Sika Kossi, On behalf of NGSEco Group, I. Durand-zaleski, 2017, European Journal of Human Genetics.

Comparative evaluation of minimally invasive ‘tibial tuberoplasty’ surgical technique versus conventional open surgery for Schatzker II–III tibial plateau fractures: design of a multicentre, randomised, controlled and blinded trial (TUBERIMPACT study)

I. Durand-zaleski, P. Ingrand, P. Rigoard, 2019, BMJ Open.

Influence of Time, Activities, and Memory on the Assessment of Chronic Low Back Pain Intensity

I. Durand-zaleski, Y. Henrotin, S. Perrot, 2009, Spine.

The Challenge of Sustainable Access to Telemonitoring Tools for People with Diabetes in Europe: Lessons from COVID-19 and Beyond

I. Durand-zaleski, A. Cicchetti, Virginia Bellido, 2021, Diabetes Therapy.

Cost‐effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases

I. Durand-zaleski, T. Allen-Mersh, M. Davies, 1998, Cancer.

Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

I. Durand-zaleski, C. Cordonnier, F. Hemery, 2017, BMC Infectious Diseases.

Developments in Idiopathic Short Stature: Cost versus Allocation of Resources

I. Durand-zaleski, 2011, Hormone Research in Paediatrics.

A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.

S. Chevret, I. Durand-zaleski, M. Cavazzana‐Calvo, 2006, Haematologica.

Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.

I. Durand-zaleski, A. Caumont-Prim, L. Mouthon, 2020, Clinical immunology.

Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis.

P. Ravaud, I. Durand-zaleski, É. Perrodeau, 2019, Clinical and experimental rheumatology.

[Unilateral inguinal hernia in infants: costs, risks and benefits of herniography? Results].

I. Durand-zaleski, O. Lucidarme, M. Gruner, 1995, Journal de radiologie.

Costs and benefits of On-Demand HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men Analysis of the ANRS IPERGAY study with a one-year follow-up.

C. Tremblay, I. Durand-zaleski, B. Spire, 2017, AIDS.

Gender Differences in Hospital Mortality and Use of Percutaneous Coronary Intervention in Acute Myocardial Infarction: Microsimulation Analysis of the 1999 Nationwide French Hospitals Database

I. Durand-zaleski, P. Steg, Carine Milcent, 2007, Circulation.

Targeted HIV Screening in Eight Emergency Departments: The DICI‐VIH Cluster‐Randomized Two‐Period Crossover Trial

G. Verbeke, I. Durand-zaleski, G. Hejblum, 2017, Annals of emergency medicine.

A first national survey of knowledge, attitudes and behaviours towards schizophrenia, bipolar disorders and autism in France

M. Leboyer, I. Durand-zaleski, F. Rouillon, 2012, BMC Psychiatry.

Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial

M. Wainberg, C. Delaugerre, C. Tremblay, 2018, Open forum infectious diseases.

A break-even price calculation for the use of sirolimus-eluting stents in angioplasty.

I. Durand-zaleski, J. Galanaud, Juliette Delavennat, 2003, Clinical therapeutics.

Early tracheotomy versus prolonged endotracheal intubation in unselected severely ill ICU patients

T. Similowski, I. Durand-zaleski, P. Chardon, 2008, Intensive Care Medicine.

Prévention des exacerbations de BPCO : un enjeu fondamental

T. Similowski, N. Roche, I. Durand-zaleski, 2012 .

[Prevention of COPD exacerbation: a fundamental challenge].

T. Similowski, N. Roche, I. Durand-zaleski, 2012, Revue des maladies respiratoires.

HIV-1 Drug Resistance Genotyping

I. Durand-zaleski, C. Chaix-couturier, K. Phillips, 2000, PharmacoEconomics.

The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France.

I. Durand-zaleski, B. Housset, B. Detournay, 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Respiratory support in COPD patients after acute exacerbation with monitoring the quality of support (Rescue2-monitor): an open-label, prospective randomized, controlled, superiority clinical trial comparing hospital- versus home-based acute non-invasive ventilation for patients with hypercapnic chr

A. Cuvelier, I. Durand-zaleski, J. Winck, 2020, Trials.

Cost-effectiveness of computed tomography coronary angiography versus conventional invasive coronary angiography

G. Chatellier, I. Durand-zaleski, P. Guéret, 2015, The European Journal of Health Economics.

Cardiovascular Magnetic Resonance may avoid unnecessary coronary angiography in patients with unexplained left ventricular systolic dysfunction: a retrospective diagnostic pilot study.

I. Durand-zaleski, G. Jondeau, A. Pathak, 2020, Journal of cardiac failure.

Impact of comprehensive geriatric assessment on survival, function, and nutritional status in elderly patients with head and neck cancer: protocol for a multicentre randomised controlled trial (EGeSOR)

I. Durand-zaleski, S. Bastuji‐Garin, H. de Kermadec, 2014, BMC Cancer.

[Economic environment and blood transfusion].

I. Durand-zaleski, 2015, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

Structural Heart Disease Transcatheter Aortic Valve Implantation

I. Durand-zaleski, M. Brunn, 2013 .

A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry

E. Andrès, I. Durand-zaleski, P. Ohlmann, 2023, Medicina.

Trends in resource use and effectiveness of ultrasound detection of fetal structural anomalies in France: a multiple registry-based study

F. Dhombres, I. Durand-zaleski, C. Ferrier, 2019, BMJ Open.

Effect of Prehabilitation Before Total Knee Replacement for Knee Osteoarthritis on Functional Outcomes

D. Biau, I. Boutron, I. Durand-zaleski, 2022, JAMA network open.

Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society

R. Lipton, H. Diener, T. Kurth, 2021, Cephalalgia : an international journal of headache.

The value of irbesartan in the management of hypertension

I. Durand-zaleski, O. Pirk, C. Hacker, 2009, Expert opinion on pharmacotherapy.

Comparing cancer care, outcomes, and costs across health systems: charting the course.

A. Mariotto, G. Gatta, I. Durand-zaleski, 2013, Journal of the National Cancer Institute. Monographs.

Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trial

E. Vicaut, I. Durand-zaleski, G. Lemesle, 2021, Clinical cardiology.

Is Europe putting theory into practice? A qualitative study of the level of self-management support in chronic care management approaches

C. Knai, I. Durand-zaleski, A. Sarría-Santamera, 2013, BMC Health Services Research.

[The cost of schizophrenia: a literature review].

I. Durand-zaleski, K. Chevreul, N. Charrier, 2013, L'Encephale.

Organisational Impact of a Remote Patient Monitoring System for Heart Failure Management: The Experience of 29 Cardiology Departments in France

I. Durand-zaleski, F. Roubille, G. Mercier, 2023, International journal of environmental research and public health.

Clinical and economic aspects of newborn screening for severe combined immunodeficiency: DEPISTREC study results.

A. Fischer, C. Picard, I. Durand-zaleski, 2019, Clinical immunology.

Down's syndrome screening with nuchal translucency at 12(+0)-14(+0) weeks and maternal serum markers at 14(+1)-17(+0) weeks: a prospective study.

Y. Ville, H. Cuckle, I. Durand-zaleski, 2002, Human reproduction.

Divergent COVID-19 vaccine policies: Policy mapping of ten European countries

I. Durand-zaleski, A. Torbica, Elias Mossialos, 2023, Vaccine.

The cost of mental health: Where do we stand in France?

M. Leboyer, C. Laidi, O. Godin, 2023, European Neuropsychopharmacology.

How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example

I. Durand-zaleski, M. Azizi, M. Darlington, 2018, Blood pressure.

Efficacy of double-balloon enteroscopy for small-bowel polypectomy: clinical and economic evaluation

G. Chatellier, T. Ponchon, J. Saurin, 2017, Therapeutic advances in gastroenterology.

Effectiveness and cost-effectiveness of a telemedicine programme for preventing unplanned hospitalisations of older adults living in nursing homes: the GERONTACCESS cluster randomized clinical trial

I. Durand-zaleski, P. Preux, C. Laubarie-Mouret, 2022, BMC geriatrics.

Quality of life instruments used in mental health research: Properties and utilization

M. Leboyer, I. Durand-zaleski, S. Simon, 2014, Psychiatry Research.

External cephalic version with epidural anaesthesia after failure of a first trial with beta‐mimetics

I. Durand-zaleski, F. Goffinet, I. Nisand, 2000, BJOG : an international journal of obstetrics and gynaecology.

The cost of mental disorders in France

M. Leboyer, I. Durand-zaleski, K. Chevreul, 2013, European Neuropsychopharmacology.

Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis

I. Durand-zaleski, C. Desnuelle, E. Delmont, 2018, Brain and behavior.

Does lay media ranking of hospitals reflect lower mortality in treating acute myocardial infarction?

Isabelle Durand-Zaleski, I. Durand-zaleski, P. Steg, 2012, Archives of cardiovascular diseases.

Multicolumn spinal cord stimulation for significant low back pain in failed back surgery syndrome: design of a national, multicentre, randomized, controlled health economics trial (ESTIMET Study).

E. Cuny, J. Régis, P. Mertens, 2015, Neuro-Chirurgie.

DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction.

R. Porcher, S. Chevret, C. Chastang, 2004, European heart journal.

Combined use of a broad-panel respiratory multiplex PCR and procalcitonin to reduce duration of antibiotics exposure in patients with severe community-acquired pneumonia (MULTI-CAP): a multicentre, parallel-group, open-label, individual randomised trial conducted in French intensive care units

B. Souweine, J. Timsit, I. Durand-zaleski, 2021, BMJ Open.

Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost‐effective

I. Durand-zaleski, D. Costagliola, S. Loubière, 2001, Vox sanguinis.

Early detection and curative treatment of hepatocellular carcinoma: A cost‐effectiveness analysis in France and in the United States

I. Durand-zaleski, C. Cagnot, P. Nahon, 2017, Hepatology.

CARING FOR THE CRITICALLY ILL PATIENT Paresis Acquired in the Intensive Care Unit A Prospective Multicenter Study

J. Lefaucheur, I. Durand-zaleski, H. Outin, 2002 .

Editor's Choice - A Study of the Cost-effectiveness of Fenestrated/branched EVAR Compared with Open Surgery for Patients with Complex Aortic Aneurysms at 2 Years.

I. Durand-zaleski, J. Becquemin, C. Quélen, 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision.

F. Guillemin, I. Durand-zaleski, C. Roux, 2013, Joint, bone, spine : revue du rhumatisme.

How much do cancer specialists earn? A comparison of physician fees and remuneration in oncology and radiology in high-income countries.

I. Durand-zaleski, S. Thomson, S. Boyle, 2017, Health policy.

Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort

F. Guillemin, I. Durand-zaleski, X. Mariette, 2014, PloS one.

Paris MEM: a study protocol for an effectiveness and efficiency trial on the treatment of traumatic stress in France after the 2015–16 terrorist attacks

B. Millet, G. Vaiva, M. Krebs, 2019, BMC Psychiatry.

Editor's choice - thirty day outcomes and costs of fenestrated and branched stent grafts versus open repair for complex aortic aneurysms.

J Marzelle, I. Durand-zaleski, J. Becquemin, 2015, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Intensive care use in a developing country: a comparison between a Tunisian and a French unit

F. Lemaire, C. Brun-Buisson, I. Durand-zaleski, 1998, Intensive Care Medicine.

PCN81 Cost-Effectiveness Analysis of Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous CELL Carcinoma in Patients Whose Tumor Expressed Programmed Death-Ligand 1 at Combined Positive Score ≥1 in France

M. Massetti, R. Borse, I. Durand-zaleski, 2020 .

Cost-effectiveness of acupuncture versus standard care for pelvic and low back pain in pregnancy: A randomized controlled trial

I. Durand-zaleski, L. Gambotti, A. Mallet, 2019, PloS one.

ÉCONOMIQUE EN RADIOLOGIE Economic assessment in radiology

M. Reiser, I. Durand-zaleski, S. Soimakallio, 1998 .

Modelling of decision analysis and costs

I. Durand-zaleski, C. Chaix, 1998, European Radiology.

Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.

I. Durand-zaleski, P. Piedbois, A. Bellanger, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Meta-Analysis Group In Cancer.

V. Sondak, M. Buyse, R. Carlson, 1999, Critical reviews in oncology/hematology.

Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer.

V. Sondak, M. Buyse, R. Carlson, 1997, Journal of the National Cancer Institute.

Decrementally cost-effective health technologies in non-inferiority studies: A systematic review

I. Durand-zaleski, M. Darlington, R. Scarica, 2022, Frontiers in Pharmacology.

Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women

I. Durand-zaleski, A. Rousseau, T. Simon, 2018, BMC Pregnancy and Childbirth.

France: Health system review.

I. Durand-zaleski, K. Chevreul, P. Mladovsky, 2010, Health systems in transition.

Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception

I. Durand-zaleski, P. Durieux, S. Gainotti, 2008, Journal of Medical Ethics.

Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction

I. Durand-zaleski, P. Henry, D. Carrié, 2009 .

Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction: insights from the TYPHOON trial.

I. Durand-zaleski, P. Henry, D. Carrié, 2009, Applied health economics and health policy.

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study

I. Durand-zaleski, P. Chauvin, P. Souquet, 2018, BMC Cancer.

MOdified DIagnostic strateGy to safely ruLe-out pulmonary embolism In the emergency depArtment: study protocol for the Non-Inferiority MODIGLIANI cluster cross-over randomized trial

I. Durand-zaleski, S. Jiménez, T. Simon, 2020, Trials.

The impact of nurse-driven targeted HIV screening in 8 emergency departments: study protocol for the DICI-VIH cluster-randomized two-period crossover trial

I. Durand-zaleski, G. Hejblum, F. Lert, 2015, BMC Infectious Diseases.

Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France

H. Leleu, I. Durand-zaleski, A. Vimont, 2021, The European Journal of Health Economics.

Additional, Mechanized Upper Limb Self-Rehabilitation in Patients With Subacute Stroke

I. Durand-zaleski, B. Médée, O. Rémy-Néris, 2021, Stroke.

Markov Models For Health Economic Evaluation Modelling In R With The Heemod Package

I. Durand-zaleski, K. Zarca, A. Filipovic-Pierucci, 2016 .

Clinical course and cost assessment of infants with a first episode of acute bronchiolitis presenting to the emergency department: Data from the GUERANDE clinical trial

I. Durand-zaleski, R. Epaud, L. Titomanlio, 2021, Pediatric pulmonology.

Prenatal and post-natal cost of small for gestational age infants: a national study

I. Durand-zaleski, O. Baud, V. Tsatsaris, 2017, BMC Health Services Research.

Global Challenge of Healthcare Rationing

I. Durand-zaleski, 2000, BMJ : British Medical Journal.

Implementing Technologies: Assessment of Telemedicine Experiments in the Paris Region: Reasons for Success or Failure of the Evaluations and of the Deployment of the Projects

I. Durand-zaleski, K. Zarca, A. Le Bras, 2023, International journal of environmental research and public health.

The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis

F. Roudot-thoraval, C. Brun-Buisson, I. Durand-zaleski, 2003, Intensive Care Medicine.

Paresis Acquired in the Intensive Care Unit

J. Lefaucheur, I. Durand-zaleski, J. Carlet, 2008 .

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts

I. Durand-zaleski, J. Penrod, F. Cotté, 2022, Cancers.

Costs of Intermittent Versus Continuous Antiretroviral Therapy in Patients With Controlled HIV Infection: A Substudy of the ANRS 106 Window Trial

I. Durand-zaleski, J. Molina, B. Marchou, 2008, Journal of acquired immune deficiency syndromes.

Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

V. de Lédinghen, J. Zucman‐Rossi, M. Ronot, 2021, JHEP reports : innovation in hepatology.

Burden of breast cancer with brain metastasis: a French national hospital database analysis

I. Durand-zaleski, F. Cotté, G. Vidal-Trécan, 2012, Journal of medical economics.

Impact of guidelines to alter antitetanus prophylaxis practices and reduce costs in the emergency department.

C. Chastang, I. Durand-zaleski, D. Elkharrat, 1999, American journal of therapeutics.

In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013

I. Durand-zaleski, G. Nachbaur, F. Maunoury, 2016, PloS one.

Feasibility and efficacy of a supervised home-based physical exercise program for metastatic cancer patients receiving oral targeted therapy: study protocol for the phase II/III - UNICANCER SdS 01 QUALIOR trial

S. Salas, I. Durand-zaleski, S. Nénan, 2020, BMC Cancer.

Modeling the Outcome of Systematic TPMT Genotyping or Phenotyping Before Azathioprine Prescription: A Cost-Effectiveness Analysis

G. Chatellier, M. Loriot, I. Durand-zaleski, 2019, Molecular Diagnosis & Therapy.

Reducing the number of T3 orders in the Paris hospital network: towards better appropriatness of thyroid function test prescription.

I. Durand-zaleski, J. Coste, M. Toubert, 2003, Annales d'endocrinologie.

The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study.

O. Hanon, I. Durand-zaleski, P. Sinnaeve, 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database

I. Durand-zaleski, G. Nachbaur, F. Maunoury, 2017, Current medical research and opinion.

Improving glycaemic control of patients with Type 2 diabetes in a primary care setting: a French application of the Staged Diabetes Management programme

G. Charpentier, I. Durand-zaleski, C. Attali, 2004, Diabetic medicine : a journal of the British Diabetic Association.

543 Multicenter, randomized, controlled, double-blind trial comparing albumin with polygeline for intravascular fluid loading in patients with cirrhosis and ascites

I. Durand-zaleski, R. Moreau, D. Valla, 2003 .

Deep Brain Stimulation Impact on Social and Occupational Functioning in Parkinson's Disease with Early Motor Complications

G. Deuschl, M. Vidailhet, A. Schnitzler, 2020, Movement disorders clinical practice.

Place of patient-reported outcomes & experiences measurements (PROMS/PREMS) in the assessment and pricing of Health technologies in France.

O. Chassany, P. Auquier, I. Durand-zaleski, 2022, Therapie.

Parkinson’s disease with early motor complications: predicting EQ-5D- 3L utilities from PDQ-39 data in the EARLYSTIM trial

I. Durand-zaleski, W. Schüpbach, M. Gorecki, 2020, Health and Quality of Life Outcomes.

EVIDENCE REQUIRED BY HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT BODIES EVALUATING DIAGNOSTIC OR PROGNOSTIC ALGORITHMS THAT INCLUDE OMICS DATA

Alexandre Barna, Teresita M Cruz-Sanchez, Karen Berg Brigham, 2018, International Journal of Technology Assessment in Health Care.

Title : The sequence effect in time trade-off elicitation

I. Durand-zaleski, M. Schwarzinger, Thea Herz, 2011 .

ICUs: from performance appraisal to executive dashboard?

I. Durand-zaleski, C. Alberti, 2007, Intensive Care Medicine.

Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France

Frédéric Lecouvet, Kevin Zarca, Olivier Cussenot, 2020, BMC Medical Imaging.

Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data

I. Durand-zaleski, G. Nachbaur, F. Maunoury, 2018, BMC Cancer.

Improving economic evaluations in stroke: A report from the ESO Health Economics Working Group

A. Meretoja, J. Saver, I. Durand-zaleski, 2020, European stroke journal.

Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial

D. Krieger, M. Macleod, S. Schwab, 2019, European stroke journal.

Melatonin for prevention of postoperative delirium after lower limb fracture surgery in elderly patients (DELIRLESS): study protocol for a multicentre randomised controlled trial

I. Durand-zaleski, S. Dahmani, S. Molliex, 2021, BMJ Open.

An attempt to save money by using mandatory practice guidelines in france

Isabelle Durand-Zaleski, Claudine Blum-Boisgard, I. Durand-zaleski, 1997, BMJ.

Infection risk and cost-effectiveness of commercial bags or glass bottles for total parenteral nutrition.

C. Brun-Buisson, I. Durand-zaleski, O. Langeron, 1997 .

Direct medical cost of bipolar disorder: Insights from the FACE-BD longitudinal cohort.

M. Leboyer, B. Aouizerate, F. Bellivier, 2022, Journal of affective disorders.

Usefulness of consensus conferences: the case of albumin

F. Lemaire, I. Durand-zaleski, P. Bierling, 1992, The Lancet.

Reply:

I. Durand-zaleski, P. Nahon, O. Seror, 2017, Hepatology.

Reply to: « Iloabuchi et al »

I. Durand-zaleski, P. Nahon, O. Seror, 2017 .

Multicentre, randomised, economic evaluation of a web-based interactive education platform, simple or enhanced, for patients with end-stage renal disease: the PIC-R trial protocol

Luc Behaghel, I. Durand-zaleski, E. Pillebout, 2022, BMJ Open.

Prognostic models for short-term annual risk of severe complications and mortality in patients living with type 2 diabetes using a national medical claim database

H. Leleu, I. Durand-zaleski, S. Béliard, 2023, Diabetology & Metabolic Syndrome.

Making Choices in Hospital Resources Allocation: The Use of an Assessment Tool to Decide Which New Projects Are Financed

F. Lemaire, I. Durand-zaleski, E. Zafrani, 1996, International Journal of Technology Assessment in Health Care.

Costs and Benefits of Measures to Prevent Needlestick Injuries in a University Hospital

F. Roudot-thoraval, I. Durand-zaleski, O. Montagne, 1999, Infection Control & Hospital Epidemiology.

Geographic disparities in access to organ transplant in France

F. Roudot-thoraval, I. Durand-zaleski, D. Houssin, 2003, Transplantation.

Innovative Curative Treatment of Beta Thalassemia: Cost-Efficacy Analysis of Gene Therapy Versus Allogenic Hematopoietic Stem-Cell Transplantation.

I. Durand-zaleski, M. Ghardallou, S. Blanche, 2019, Human gene therapy.

Cost-effectiveness of acupuncture versus standard care for pelvic and low back pain in pregnancy: A randomized controlled trial

I. Durand-zaleski, L. Gambotti, A. Mallet, 2019, PLoS ONE.

[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer].

I. Durand-zaleski, V. Girre, E. Pujade-Lauraine, 2003, Bulletin du cancer.

Is Europe putting theory into practice? A study of the level of Self-Management Support in coordinated care approaches for chronically ill

C. Knai, I. Durand-zaleski, A. Sarría-Santamera, 2013 .

Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project

G. Lewison, R. Busse, I. Durand-zaleski, 2016, Health Research Policy and Systems.

Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality.

Ruth Etzioni, I. Lansdorp-Vogelaar, I. Durand-zaleski, 2013, Journal of the National Cancer Institute. Monographs.

Editorial: Pharmacoeconomics in the era of health technology assessment and outcomes research to prioritize resource use, innovation and investment

I. Durand-zaleski, K. Cohen, M. Schwenkglenks, 2023, Frontiers in Pharmacology.

Implementation of Nurse-Driven HIV Screening Targeting Key Populations in Emergency Departments: A Multilevel Analysis From the DICI-VIH Trial.

G. Verbeke, I. Durand-zaleski, F. Lert, 2019, Worldviews on evidence-based nursing.

Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data

I. Durand-zaleski, G. Nachbaur, F. Maunoury, 2018, BMC Cancer.

Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).

A. Luciani, C. Tournigand, I. Sobhani, 2017 .

Is there an optimal strategy for real‐time continuous glucose monitoring in pediatrics? A 12‐month French multi‐center, prospective, controlled randomized trial (Start‐In!)

I. Durand-zaleski, J. Carel, V. Sulmont, 2019, Pediatric diabetes.

Quantifying patient centered outcomes associated with the use of bilateral endobronchial coil treatment in patients with severe emphysema

M. Sculpher, D. Slebos, M. Munavvar, 2018, Current medical research and opinion.

Methods and interest of noninvasive assessment of liver fibrosis are still in debate

I. Durand-zaleski, F. Degos, L. Lebrun, 2011, Hepatology.

FROM CLINICAL RECOMMENDATIONS TO MANDATORY PRACTICE

P. Ravaud, I. Durand-zaleski, C. Chaix-couturier, 2000, International Journal of Technology Assessment in Health Care.

From 'Do No Harm' to 'Do Maximal Good': an evolving concept.

I. Durand-zaleski, D. Holmes, W. Wijns, 2020, European heart journal.

Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies

I. Durand-zaleski, A. Vivot, J. Li, 2020, Expert review of pharmacoeconomics & outcomes research.

Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial

S. Cook, I. Durand-zaleski, P. Sinnaeve, 2019, Value in Health.

Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease

I. Durand-zaleski, R. Roussel, F. Hyafil, 2023, EJNMMI Research.

[Does continuing medical education improve the way physicians conduct their practice?].

P. Ravaud, I. Durand-zaleski, P. Durieux, 1999, Presse medicale.

Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention

I. Durand-zaleski, E. Teiger, S. Marque, 2016, Open Heart.

Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial

A. Cremer, P. Gosse, G. Chatellier, 2017, Journal of the American Heart Association.

Correction: Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Dede Sika Kossi, On behalf of NGSEco Group, I. Durand-zaleski, 2018, European Journal of Human Genetics.

Comparing cancer care, outcomes, and costs across health systems: charting the course.

A. Mariotto, G. Gatta, I. Durand-zaleski, 2013, Journal of the National Cancer Institute. Monographs.

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience

G. Chatellier, P. Laurent-Puig, I. Durand-zaleski, 2013, PloS one.

Divergent COVID-19 vaccine policies: Policy mapping of ten European countries

I. Durand-zaleski, A. Torbica, Elias Mossialos, 2023, Vaccine.

International practitioner data bank as a quality tool: are we using behavior control in the right environment?

I. Durand-zaleski, G. De Pourvourville, 1997, International journal for quality in health care : journal of the International Society for Quality in Health Care.

Do We Need to Assess Quality-of-Life with Both the St George’s Respiratory Questionnaire and the EuroQol 5-Dimension Questionnaire in a Clinical Study with an Economic Component: Insights from the REVOLENS Study in Severe Emphysema

C. Marquette, S. Leroy, I. Durand-zaleski, 2020, International journal of chronic obstructive pulmonary disease.

Do We Need to Assess Quality-of-Life with Both the St George ’ s Respiratory Questionnaire and the EuroQol 5-Dimension Questionnaire in a Clinical Study with an Economic Component: Insights from the REVOLENS Study in Severe Emphysema

S. Leroy, I. Durand-zaleski, G. Deslée, 2020 .

Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception

I. Durand-zaleski, P. Durieux, S. Gainotti, 2008, Journal of Medical Ethics.

Prevalence and risk factors for carriage of methicillin-resistant Staphylococcus aureus at admission to the intensive care unit: results of a multicenter study.

S. Chevret, C. Chastang, I. Durand-zaleski, 2003, Archives of internal medicine.

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Lionel Perrier, Isabelle Durand-Zaleski, Rajae Touzani, 2018, European Journal of Human Genetics.

The cost of mental disorders in France

M. Leboyer, I. Durand-zaleski, K. Chevreul, 2013, European Neuropsychopharmacology.

A Cost Analysis of the Prevention of End-stage Renal Disease

I. Durand-zaleski, S. Bastuji‐Garin, G. Rostoker, 1996, Medical decision making : an international journal of the Society for Medical Decision Making.

Total parenteral nutrition

C. Brun-Buisson, I. Durand-zaleski, O. Langeron, 2012 .

End-of life medical spending and care pathways in the last 12 months of life: A comprehensive analysis of the national claims database in France

I. Durand-zaleski, J. Texereau, L. Champion, 2023, Medicine.

Work Productivity Loss in Early Arthritis During the First 3 Years of Disease: A Study From a French National Multicenter Cohort

F. Guillemin, I. Durand-zaleski, F. Berenbaum, 2014, Arthritis care & research.

Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial.

C. Marquette, J. Vergnon, L. Thiberville, 2016, JAMA.

Reducing unnecessary laboratory use with new test request form: example of tumour markers

I. Durand-Zaleski, F. Roudot-thoraval, I. Durand-zaleski, 1993, The Lancet.

Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial

A. Cremer, P. Gosse, G. Chatellier, 2017, Journal of the American Heart Association.

I. Durand-zaleski, S. Bastuji‐Garin, H. de Kermadec, 2014, BMC Cancer.

Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma.

G. Chatellier, V. Vilgrain, I. Durand-zaleski, 2021, Clinical therapeutics.

Incidence and characteristics of rhegmatogenous retinal detachment during coronavirus-19 pandemic: A French study

J. Sahel, I. Durand-zaleski, R. Tadayoni, 2022, European Journal of Ophthalmology.